Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2019 | Lymphoma: odronextamab (REGN197)

Rajat Bannerji • 14 Jun 2019
EHA 2019
Diffuse Large B-Cell Lymphoma Follicular Lymphoma Lymphoma Non-Hodgkin Lymphoma Odronextamab

Odronextamab (REGN197) has demonstrated efficacy and an acceptable safety profile in the treatment of follicular lymphoma, diffuse large B-cell lymphoma and other B cell non-Hodgkin lymphoma subtypes. Rajat Bannerji, MD, PhD, Rutgers Cancer institute of New Jersey, NJ, discusses this at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Rajat Bannerji

Odronextamab in R/R B-cell non-Hodgkin lymphomas 6:26
Odronextamab in R/R B-cell non-Hodgkin lymphomas
Rajat Bannerji • 9 Dec 2020

Related Videos

Preliminary findings from a trial of a novel CD30-directed antibody-drug conjugate in R/R lymphomas 1:57
Preliminary findings from a trial of a novel CD30-directed antibody-drug conjugate in R/R lymphomas
Swetha Thiruvengadam • 8 Dec 2025
Interim analysis of a Phase II trial of epcoritamab plus lenalidomide in treatment-naive FL 1:14
Interim analysis of a Phase II trial of epcoritamab plus lenalidomide in treatment-naive FL
Swetha Thiruvengadam • 8 Dec 2025
Primary Phase III results from the EPCORE FL-1 trial: epcoritamab plus R2 versus R2 for R/R FL 3:07
Primary Phase III results from the EPCORE FL-1 trial: epcoritamab plus R2 versus R2 for R/R FL
Lorenzo Falchi • 6 Dec 2025
Phase II trial of mosunetuzumab with response-driven lenalidomide augmentation in FL and MZL 3:05
Phase II trial of mosunetuzumab with response-driven lenalidomide augmentation in FL and MZL
Adam Olszewski • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals